Peripartum Cardiomyopathy

Healthy heart muscle
Healthy heart muscle
A dilated heart, its chambers widened and walls thinned
A dilated heart, its chambers widened and walls thinned

Overview

Peripartum cardiomyopathy (PPCM) is an idiopathic dilated cardiomyopathy presenting in the final month of pregnancy or within 5 months postpartum (Pearson 2000 Working Group definition) in the absence of prior heart disease and in the absence of any identifiable cause of heart failure. The heart dilates and ejection fraction falls below 45%, causing heart failure symptoms in a previously healthy young woman. PPCM is one of the most important causes of maternal mortality in the modern era.

Despite its severity, PPCM is frequently misdiagnosed as normal pregnancy-related breathlessness. Dyspnea during pregnancy is ubiquitous, but orthopnea (breathlessness when lying flat) is NOT a normal feature of pregnancy; it is a heart-failure warning sign, and an echocardiogram (heart ultrasound) is the test that shows whether the heart muscle is failing. Delays in diagnosis worsen outcomes and increase the risk of irreversible ventricular remodeling, thromboembolic complications, and sudden death.

Incidence varies widely by population: approximately 1:1,000–3,000 live births globally; in Nigeria and Haiti approximately 1:100–1:300; Japan among the lowest reported rates; the United States approximately 1:2,500. Rates appear to be increasing, most likely reflecting improved detection and reporting rather than a true rise in incidence.

Back to Table of Contents

Epidemiology and Risk Factors

PPCM does not occur at random — multiple demographic, obstetric, and systemic risk factors have been consistently identified across large registries:

Women with multiple risk factors — particularly African American ethnicity, preeclampsia, and advanced maternal age — carry the highest absolute risk; in them, breathlessness or fluid retention out of proportion to the stage of pregnancy is a recognized reason for an early echocardiogram.

Back to Table of Contents

Pathophysiology — Prolactin, Angiogenic Imbalance, and Genetics

PPCM is not simply dilated cardiomyopathy that happens to occur during pregnancy. A specific pathophysiological mechanism distinct from other cardiomyopathies has been identified, centered on the prolactin hypothesis, with overlapping contributions from angiogenic imbalance and genetic susceptibility.

The Prolactin Hypothesis

The prolactin hypothesis was developed primarily by Hilfiker-Kleiner, Sliwa, and Fett and has become the dominant pathophysiological framework for PPCM:

  1. Oxidative stress in the peripartum heart — generated by the metabolic demands of pregnancy, breastfeeding, sleep deprivation, and hemodynamic overload — upregulates Cathepsin D, a lysosomal protease, within cardiomyocytes.
  2. Cathepsin D cleaves full-length 23 kDa prolactin into a 16 kDa anti-angiogenic prolactin fragment.
  3. This 16 kDa fragment exerts direct cardiac toxicity by: (a) inhibiting cardiomyocyte proliferation and survival; (b) inducing cardiomyocyte apoptosis; (c) impairing the cardiac microvasculature through its anti-angiogenic activity, reducing capillary density and producing ischemic myocardial injury; and (d) acting in a paracrine manner to amplify myocardial damage.
  4. Prolactin is markedly elevated throughout pregnancy and especially during breastfeeding, providing abundant substrate for 16 kDa fragment generation.
  5. The therapeutic implication is direct: bromocriptine, a dopamine agonist that suppresses prolactin secretion, would be expected to block 16 kDa fragment generation and protect the myocardium.

Angiogenic Imbalance and sFlt-1

The placenta releases anti-angiogenic sFlt-1 (soluble fms-like tyrosine kinase-1), which sequesters vascular endothelial growth factor (VEGF) and impairs cardiac microvasculature. This mechanism is also central to preeclampsia pathophysiology, explaining the strong epidemiological association between PPCM and preeclampsia — the two conditions share a common anti-angiogenic underpinning. A 2012 study by Patten and colleagues (Arany laboratory, Nature) found abnormally high sFLT1 levels in plasma from women with PPCM; in women late in pregnancy, mild heart dysfunction that caused no symptoms tracked with circulating sFLT1 levels, and in mice sFLT1 alone impaired heart function.

Supporting Evidence for the Prolactin Hypothesis

Back to Table of Contents

Genetic Basis — TTN and Other Variants

Damaging (truncating) variants in cardiomyopathy genes were found in about 15% of PPCM patients (26 of 172 women in a 2016 study) — a rate similar to the 17% seen in dilated cardiomyopathy; the 2019 European Society of Cardiology position statement puts the genetic contribution at up to 20% — suggesting that PPCM represents a genetically susceptible heart unmasked by the hemodynamic challenge of pregnancy:

Clinical Implications of Genetic Testing

Genetic testing is now recommended in PPCM by both the European Society of Cardiology and recent American guidelines. Key implications include:

Back to Table of Contents

Clinical Presentation and Diagnosis

Onset Timing

Symptoms

Symptoms mirror those of dilated cardiomyopathy and heart failure but arise in a context where many overlap with normal pregnancy:

Physical Examination

Tachycardia; laterally displaced apical impulse reflecting LV dilation; S3 gallop; mitral regurgitation murmur from annular dilation; bibasilar pulmonary crackles; elevated jugular venous pressure; and pitting edema of the lower extremities and ankles.

Diagnostic Criteria

Diagnosis is clinical, echocardiographic, and exclusionary. All three conditions are required:

  1. New onset heart failure in the last month of pregnancy or within 5 months postpartum
  2. No identifiable cause: not valvular, not congenital, not ischemic coronary disease, not previously known cardiomyopathy
  3. LV systolic dysfunction: EF <45% on echocardiography (often severely reduced to 20–35% at presentation in acute cases)

Back to Table of Contents

Echocardiography and Cardiac Imaging

Echocardiogram — First-Line and Essential

Transthoracic echocardiography is the cornerstone of diagnosis and follow-up in PPCM. Key findings include:

LV EF at presentation and at 6 months post-diagnosis is the single most important prognostic marker in PPCM.

Cardiac Magnetic Resonance Imaging

Cardiac magnetic resonance imaging (MRI) is indicated when echocardiographic windows are suboptimal or the diagnosis is uncertain:

Biomarkers

BNP and NT-proBNP are markedly elevated in PPCM, correlating with disease severity and falling with effective treatment. Serial measurements are valuable to track therapeutic response. Troponin elevation reflects myocardial injury and often correlates with LGE extent on magnetic resonance imaging. C-reactive protein (CRP) may reflect the inflammatory component of PPCM pathophysiology.

Coronary Assessment

Spontaneous coronary artery dissection (SCAD) is a peripartum-specific cause of myocardial infarction that can mimic PPCM in a young woman presenting with chest pain and heart failure. SCAD is excluded with computed tomography (CT) coronary angiography or invasive coronary angiography, and is usually treated conservatively (PCI worsens dissection propagation in most cases). Standard coronary artery disease is uncommon at this age but possible in the setting of metabolic syndrome or severe preeclampsia-related vascular injury.

Holter Monitoring

Arrhythmias — atrial fibrillation, nonsustained ventricular tachycardia, and frequent PVCs — are common in PPCM. Holter monitoring is part of ICD decision-making and is standard in patients with palpitations or fainting (syncope).

Back to Table of Contents

Standard Heart Failure Treatment (Antepartum)

During pregnancy, medicines that harm the unborn baby (teratogenic medicines) are not used. Management focuses on pregnancy-safe agents that reduce hemodynamic burden and prevent complications:

Beta-Blockers (First-Line Antepartum)

Diuretics

Hydralazine + Nitrates (Afterload Reduction)

Digoxin

Safe in pregnancy. Provides modest positive inotropy and rate control in atrial fibrillation. Limited contemporary use in sinus rhythm given availability of superior agents postpartum, but useful for refractory heart failure or rate control antepartum.

Anticoagulation (Antepartum)

Delivery Planning

Vaginal delivery is generally preferred in stable PPCM — cardiac output perturbations with vaginal delivery are more predictable than with cesarean section under general anesthesia. Epidural analgesia reduces pain-related catecholamine surges and is beneficial in cardiac patients. Assisted delivery (forceps or vacuum) is planned when prolonged pushing would strain the heart. Oxytocin is given as a slow infusion, not a bolus; ergometrine is contraindicated due to severe vasoconstriction. Hemodynamic monitoring with arterial line — and pulmonary artery catheter in very severe cases — guides real-time management.

Back to Table of Contents

Standard Heart Failure Treatment (Postpartum)

After delivery, the full guideline-directed medical therapy (GDMT) arsenal for heart failure with reduced ejection fraction (HFrEF) becomes available. The goal is maximal medical therapy to maximize the probability of LV recovery:

ACE Inhibitors and Angiotensin Receptor Blockers

Enalapril or lisinopril are the backbone of HFrEF therapy. Low doses of enalapril during breastfeeding appear safe (minimal milk transfer). Doses are raised toward target as tolerated, with creatinine and potassium checked closely.

Sacubitril/Valsartan (ARNi)

The angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan is superior to angiotensin-converting enzyme inhibitor alone for reducing HFrEF mortality (PARADIGM-HF trial). Because sacubitril/valsartan is teratogenic, it is started only after delivery, usually after breastfeeding has ended or after the risks and benefits have been weighed with the patient. It replaces the angiotensin-converting enzyme inhibitor or angiotensin receptor blocker when added to improve EF.

Sodium-Glucose Cotransporter-2 Inhibitors

Dapagliflozin and empagliflozin carry Class 1A recommendation in HFrEF GDMT based on DAPA-HF and EMPEROR-Reduced trials. Safety during breastfeeding is unknown; they are excreted in breast milk in animal models. Using sodium-glucose cotransporter-2 (SGLT2) inhibitors versus continuing breastfeeding is a trade-off weighed with the patient.

Mineralocorticoid Receptor Antagonists (MRA)

Spironolactone or eplerenone reduce HFrEF mortality and are part of complete GDMT. Spironolactone has weak anti-androgenic effects and is generally not used during breastfeeding due to theoretical concerns for breastfed male infants; it is usually started after breastfeeding ends.

Beta-Blockers (Continued)

Carvedilol or metoprolol succinate started before delivery is continued and raised toward guideline target doses over weeks to months as blood pressure and heart rate allow. Doses are not raised rapidly during active decompensation.

Anticoagulation (Postpartum)

After delivery, LMWH is commonly switched to warfarin (target international normalized ratio (INR) 2–3) if EF remains below 30% or LV thrombus persists. Anticoagulation can be discontinued when EF has recovered to above 40–45% and thrombus has resolved. Direct oral anticoagulants (DOACs) are not recommended during breastfeeding due to inadequate safety data.

Back to Table of Contents

Bromocriptine — The Prolactin Hypothesis

Bromocriptine is a dopamine D2 receptor agonist that suppresses prolactin secretion from the anterior pituitary. By blocking prolactin, bromocriptine prevents the generation of the cardiotoxic 16 kDa prolactin fragment by Cathepsin D, protecting the myocardium from prolactin-mediated anti-angiogenic and pro-apoptotic injury.

The South African Pilot Study (Sliwa et al., Circulation 2010)

This single-centre, open-label, randomized proof-of-concept pilot study enrolled 20 South African women with newly diagnosed severe PPCM: 10 received standard heart failure therapy and 10 received standard therapy plus bromocriptine for 8 weeks. At 6 months, ejection fraction in the bromocriptine group had risen from 27% to 58%, against 27% to 36% with standard care (a significant difference). One woman died in the bromocriptine group and four in the standard-care group, and a poor outcome (death, severe heart-failure symptoms or an ejection fraction below 35% at 6 months) occurred in 1 of 10 (10%) versus 8 of 10 (80%). This was the first prospective evidence for bromocriptine as a PPCM-specific treatment; the authors wrote that the number of patients was small and the results cannot be considered definitive. Critics note the small sample size and that the South African population may not fully generalize to other settings.

Subsequent Evidence

Practical Use

Back to Table of Contents

Advanced Therapies and Device Management

Wearable Cardioverter-Defibrillator

Many PPCM patients present with an EF below 35% — the standard threshold for permanent ICD implantation. However, PPCM has a high recovery rate (in the North American IPAC study, 72% of women reached an EF of 50% or more by 1 year). Implanting a permanent ICD in the acute phase is premature and exposes patients who will recover to an unnecessary device. A wearable cardioverter-defibrillator bridges this gap: it provides continuous protection against sudden cardiac death for 3–6 months while recovery is awaited. If EF has not recovered above 35% at 6 months, a permanent ICD is then implanted. This strategy uniquely distinguishes PPCM management from other cardiomyopathy contexts where ICD implantation typically follows immediately upon meeting criteria.

Cardiac Resynchronization Therapy (CRT)

If QRS prolongation (left bundle branch block morphology, QRS duration above 150 ms) persists at 3–6 months in the setting of EF below 35%, cardiac resynchronization therapy with defibrillation capability (CRT-D) is indicated. CRT improves LV mechanical synchrony and can augment EF recovery in PPCM just as in other HFrEF with LBBB.

Left Ventricular Assist Device (LVAD)

LVAD implantation is indicated for cardiogenic shock or rapidly deteriorating PPCM failing maximal medical therapy. PPCM has a notably higher bridge-to-recovery rate compared to other DCM causes, and some patients can successfully undergo LVAD explantation after sufficient cardiac recovery. For patients without recovery, LVAD serves as a bridge to cardiac transplantation.

Cardiac Transplantation

Cardiac transplantation is required in 1–5% of PPCM patients who do not recover LV function despite LVAD support and maximal medical therapy after 6–12 months. Post-transplant outcomes in PPCM are comparable to other DCM etiologies.

Endomyocardial Biopsy

Endomyocardial biopsy is rarely needed but is considered when the diagnosis is uncertain — specifically to exclude giant cell myocarditis, which requires immunosuppressive therapy and has a far worse prognosis than PPCM if untreated. Giant cell myocarditis can present identically to PPCM in the peripartum period.

Acute Decompensated PPCM

Intensive care unit-level management for cardiogenic shock includes vasopressors (norepinephrine plus vasopressin for refractory hypotension; epinephrine is generally not used because it has been linked with higher cardiogenic shock mortality), inodilators (dobutamine for low-output state), intra-aortic balloon pump (IABP), percutaneous ventricular assist devices (microaxial pumps), and venoarterial extracorporeal membrane oxygenation (VA-ECMO) for the most refractory cases as a bridge to LVAD or transplantation.

Back to Table of Contents

Subsequent Pregnancy Counseling

Counseling women with a history of PPCM about future pregnancies is one of the most critical and emotionally complex conversations in cardiovascular medicine. The risk of recurrence is real regardless of apparent recovery, and the stakes are high.

Risk Stratification

Two follow-up studies report outcomes of later pregnancies. In a 2001 US study of 44 women with 60 later pregnancies, heart-failure symptoms occurred in 21% of women whose heart function had returned to normal before the next pregnancy and in 44% of women with persistent dysfunction; deaths were 0% and 19%. A 2022 Israeli series of 45 women with 59 later full-term births (most with a recovered ejection fraction, average 57.7%) found only a slight fall in ejection fraction, mostly in the third trimester, relapse in 1 woman whose ejection fraction had been 55% or more and in 3 of the women whose ejection fraction had been below 55%, and no maternal deaths.

Breastfeeding and PPCM

Elevated prolactin during breastfeeding theoretically sustains the generation of the cardiotoxic 16 kDa prolactin fragment. Bromocriptine and breastfeeding do not go together — bromocriptine suppresses lactation as part of its mechanism. If bromocriptine is not used, breastfeeding may continue; the theoretical cardiac risk is part of that decision and the clinical course is monitored closely. The decision is individualized based on the patient's values and the clinical trajectory of LV recovery.

Genetic Counseling

Women with PPCM who carry a pathogenic variant — particularly TTN, LMNA, or DSP — are candidates for formal counseling at a cardiomyopathy genetics clinic. Daughters of PPCM patients with TTN truncating variants face elevated PPCM risk in their own future pregnancies, which matters before they plan families.

Back to Table of Contents

Prognosis

Recovery Rates

Predictors of Poor Prognosis

Long-Term Follow-Up

Echocardiography at 6 months is the critical decision point for ICD implantation, transplant listing, and determination of LVAD candidacy. Even after apparent full recovery, annual echocardiography for at least 5 years is recommended because late deterioration of LV function has been documented. Cardiology follow-up typically continues for life, with family planning discussions integrated into every cardiology visit. The 6-month echo is also the appropriate time to re-evaluate genetic testing results and their implications for the patient's care plan.

Back to Table of Contents

Key Research Papers

  1. Sliwa K, Fett J, Elkayam U. "Peripartum cardiomyopathy." Lancet. 2006;368(9536):687–693. — PubMed PMID: 16920474
  2. Pearson GD, Veille JC, Rahimtoola S, et al. "Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop recommendations and review." JAMA. 2000;283(9):1183–1188. — PubMed PMID: 10703781
  3. Sliwa K, Blauwet L, Tibazarwa K, et al. "Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study." Circulation. 2010;121(13):1465–1473. — PubMed PMID: 20308616
  4. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy." Cell. 2007;128(3):589–600. — PubMed PMID: 17289576
  5. McNamara DM, Elkayam U, Alharethi R, et al. "Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)." J Am Coll Cardiol. 2015;66(8):905–914. — PubMed PMID: 26293760
  6. Ware JS, Li J, Mazaika E, et al. "Shared genetic predisposition in peripartum and dilated cardiomyopathies." N Engl J Med. 2016;374(3):233–241. — PubMed PMID: 26735901
  7. Hibbard JU, Lindheimer M, Lang RM. "A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography." Obstet Gynecol. 1999;94(2):311–316. — PubMed PMID: 10432149
  8. Bauersachs J, König T, van der Meer P, et al. "Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy." Eur J Heart Fail. 2019;21(7):827–843. — PubMed PMID: 31243866
  9. Honigberg MC, Givertz MM. "Peripartum cardiomyopathy." BMJ. 2019;364:k5287. — PubMed PMID: 30700415
  10. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. "Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy." Circulation. 2010;121(20):2169–2175. — PubMed PMID: 20458010
  11. Arany Z, Elkayam U. "Peripartum cardiomyopathy." Circulation. 2016;133(14):1397–1409. — PubMed PMID: 27045128
  12. Sliwa K, Petrie MC, van der Meer P, et al. "Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the ESC Study Group on PPCM." Eur J Heart Fail. 2017;19(9):1131–1141. — PubMed PMID: 28271625
  13. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. "Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study." Eur Heart J. 2017;38(35):2671–2679. — PubMed PMID: 28934837
  14. Patten IS, Rana S, Shahul S, et al. "Cardiac angiogenic imbalance leads to peripartum cardiomyopathy." Nature. 2012;485(7398):333–338. — PubMed PMID: 22596155
  15. Bello N, Rendon ISH, Arany Z. "The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis." J Am Coll Cardiol. 2013;62(18):1715–1723. — PubMed PMID: 24013055
  16. van der Meer P, van Essen BJ, Viljoen C, et al. "Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry." Eur Heart J. 2025;46(11):1017–1027. — PubMed PMID: 39221911
  17. Adamu UG, Mojela K, Karaye KM, Tsabedze N. "Bromocriptine in peripartum cardiomyopathy: a meta-analysis with trial sequential analysis." ESC Heart Fail. 2025;12(6):4041–4054. — PubMed PMID: 41213878
  18. Wang T, Ibarra AJ, Simpson D, et al. "Bromocriptine for myocardial recovery in peripartum cardiomyopathy: design and rationale of the REBIRTH trial." JACC Heart Fail. 2026:103376. — PubMed PMID: 42911149
  19. Elkayam U, Tummala PP, Rao K, et al. "Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy." N Engl J Med. 2001;344(21):1567–1571. — PubMed PMID: 11372007
  20. Goland S, George J, Elkayam U, et al. "Contemporary outcome of subsequent pregnancies in patients with previous peripartum cardiomyopathy." ESC Heart Fail. 2022;9(6):4262–4270. — PubMed PMID: 36128657

Back to Table of Contents

Connections